64 related articles for article (PubMed ID: 1538951)
1. GM-CSF treatment of myelodysplastic syndromes: personal experience and preliminary results of a randomized international study.
Coiffier B; Bastion Y; Felman P; Tigaud JD; Bryon PA
Pathol Biol (Paris); 1992 Nov; 39(9):957-8. PubMed ID: 1538951
[No Abstract] [Full Text] [Related]
2. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
4. [Pyoderma gangrenosum aggravated by GM-CSF administration].
Perrot JL; Benoit F; Segault D; Jaubert J; Guyotat D; Claudy A
Ann Dermatol Venereol; 1992; 119(11):846-8. PubMed ID: 1301698
[No Abstract] [Full Text] [Related]
5. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
6. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of human granulocyte-macrophage colony-stimulating factor.
Sakamoto KM; Gasson JC
Int J Cell Cloning; 1991 Nov; 9(6):531-41. PubMed ID: 1770227
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of GM-CSF in patients with aplastic anemia and myelodysplastic syndrome. (CSF39-300 Study Group)].
Kitamura K; Asano S; Mizoguchi H; Takaku F
Rinsho Ketsueki; 1993 Dec; 34(12):1540-9. PubMed ID: 8295327
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of myelodysplastic syndrome-associated anaemia with rhGM-CSF.
Hansen PB; Pri TK; Hippe E
Presse Med; 1994 Jun; 23(22):1042. PubMed ID: 7971812
[No Abstract] [Full Text] [Related]
10. Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
Ganser A; Ottmann OG; Hoelzer D
Stem Cells; 1993 Nov; 11(6):465-73. PubMed ID: 8111306
[No Abstract] [Full Text] [Related]
11. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
[TBL] [Abstract][Full Text] [Related]
13. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
14. Use of granulocyte-macrophage colony-stimulating factor in patients with malignancy and bone marrow failure.
Shadduck RK; Rosenfeld CS; Sulecki M; Phillips N; Przepiorka D; Earle M; Stoller R; Jacobs S
Int J Cell Cloning; 1990 Jan; 8 Suppl 1():303-12; discussion 312-3. PubMed ID: 2182742
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human GM-CSF: present clinical results and potential use in oncologic and hematologic disorders.
Jones TC
Bull Cancer; 1991; 78(12):1155-9. PubMed ID: 1786428
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of methimazole-induced agranulocytosis with granulocyte-macrophage colony stimulating factor].
Somogyi A; Werling K; Rosta A; Láng I
Orv Hetil; 1994 Nov; 135(45):2483-5. PubMed ID: 7991239
[TBL] [Abstract][Full Text] [Related]
18. c-kit ligand augments granulocyte-macrophage colony growth from patients with 5q- syndrome.
Rosenfeld CS; Nemunaitis J; Sherer CR; Zeigler ZR; Shadduck RK
Stem Cells; 1993 Nov; 11(6):562-7. PubMed ID: 7509225
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
